In preclinical breast cancer models treated with paclitaxel and anti-TIM-3 mAb, TIM-3+ intra-tumor CD103+ dendritic cells (DCs) are a key target subset that can mobilize CD8+ T cells via CXCL9 production in response to the combination therapy [127]. Here, CD8A is linked to neoplasm.